Black Diamond Therapeutics Inc (BDTX NASDAQ) stock market data APIs
$4.5937
-0.21(-4.6%)
as of November 11, 2025
Try our APIs with
free plan!
Black Diamond Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Prev. Close
4.5937
Open
4.379
High
4.6284
Low
4.3019
52 wk Range
1.195-4.645
Market Cap
263 M
P/E Ratio
12.4865
Shares Outstanding
56 975 K
Revenue
70 000 K
EPS
-0.15
Beta
3.341
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Black Diamond Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Black Diamond Therapeutics Inc data using free add-ons & libraries
Get Black Diamond Therapeutics Inc Fundamental Data
Black Diamond Therapeutics Inc Fundamental data includes:
- Net Revenue: 70 000 K
- EBITDA: 15 146 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.226
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Black Diamond Therapeutics Inc News
New
3 Promising Penny Stocks With Market Caps Below $600M
As the U.S. market faces a challenging period with tech stocks under pressure and major indices experiencing losses, investors are exploring alternative opportunities to diversify their portfolios. Pe...
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogeni...
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of ...
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
Investors will focus on updates on lead pipeline candidate silevertinib when Black Diamond Therapeutics BDTX reports third-quarter results shortly. The Zacks Consensus Estimate for loss per share is p...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
